NVS Novartis AG Stock Quote

NVS [NYSE]

Healthcare | Drug Manufacturers - General | Switzerland

Index	-	P/E	31.37	EPS (ttm)	3.09	Insider Own	9.30%	Shs Outstand	2.29B	Perf Week	3.83%
Market Cap	235.18B	Forward P/E	15.18	EPS next Y	6.38	Insider Trans	0.00%	Shs Float	2.27B	Perf Month	6.57%
Income	7.10B	PEG	4.04	EPS next Q	1.34	Inst Own	10.20%	Short Float	0.19%	Perf Quarter	13.06%
Sales	49.58B	P/S	4.74	EPS this Y	-43.60%	Inst Trans	0.95%	Short Ratio	2.29	Perf Half Y	12.00%
Book/sh	23.84	P/B	4.06	EPS next Y	11.01%	ROA	5.70%	Target Price	107.00	Perf Year	1.75%
Cash/sh	4.48	P/C	21.64	EPS next 5Y	7.77%	ROE	13.20%	52W Range	69.18 - 99.84	Perf YTD	2.59%
Dividend	3.09	P/FCF	47.20	EPS past 5Y	-6.50%	ROI	8.60%	52W High	-2.97%	Beta	0.59
Dividend %	3.19%	Quick Ratio	0.70	Sales past 5Y	-1.90%	Gross Margin	71.20%	52W Low	40.04%	ATR	1.28
Employees	110000	Current Ratio	0.90	Sales Q/Q	0.40%	Oper. Margin	18.80%	RSI (14)	69.50	Volatility	0.98% 1.04%
Optionable	Yes	Debt/Eq	0.70	EPS Q/Q	-5.40%	Profit Margin	14.30%	Rel Volume	0.55	Prev Close	96.92
Shortable	Yes	LT Debt/Eq	0.52	Earnings	Jan 26 BMO	Payout	91.00%	Avg Volume	1.93M	Price	96.88
Recom	1.00	SMA20	4.05%	SMA50	6.96%	SMA200	10.96%	Volume	1,071,326	Change	-0.04%

Jan-15-21

Initiated

Deutsche Bank

Buy

Sep-29-20

Initiated

Berenberg

Buy

Sep-10-20

Upgrade

UBS

Neutral → Buy

Sep-01-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Jun-15-20

Upgrade

Citigroup

Neutral → Buy

Mar-10-20

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Feb-25-20

Downgrade

Guggenheim

Buy → Neutral

Apr-25-19

Upgrade

Liberum

Hold → Buy

Apr-25-19

Upgrade

Guggenheim

Neutral → Buy

Apr-10-19

Downgrade

Morgan Stanley

Equal-Weight → Underweight

Jan-02-19

Downgrade

JP Morgan

Neutral → Underweight

Dec-11-18

Resumed

Jefferies

Buy

Oct-09-18

Initiated

Guggenheim

Neutral

Sep-10-18

Upgrade

BofA/Merrill

Underperform → Buy

May-29-18

Downgrade

HSBC Securities

Buy → Hold

May-25-18

Upgrade

Credit Suisse

Underperform → Neutral

Jan-25-18

Reiterated

Leerink Partners

Outperform

$93 → $100

Dec-06-17

Downgrade

BofA/Merrill

Neutral → Underperform

Jul-26-17

Upgrade

Morgan Stanley

Underweight → Overweight

Jul-05-17

Downgrade

Credit Suisse

Neutral → Underperform

Jan-21-21 10:29AM	Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod Zacks
07:04AM	The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts Zacks
Jan-20-21 12:15PM	Top Stock Reports for Novartis, QUALCOMM & Accenture Zacks
10:30AM	TENX: Tenax Picks Up PH Precision Med Zacks Small Cap Research
Jan-15-21 09:11AM	Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status Zacks
08:14AM	Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals Zacks
Jan-14-21 04:35PM	Beigene Stock Breaks Out To Record High On Cancer Drug OK In China Investor's Business Daily
03:11PM	With Rare Speed, Gene Editing Emerges as Biotechs New Cutting Edge Barrons.com
Jan-12-21 04:31PM	Beigene Surges Closer To Breakout On $2.2 Billion Deal With Novartis Investor's Business Daily
02:58PM	Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene Zacks
08:15AM	The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga
Jan-11-21 04:30PM	Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene GlobeNewswire
Dec-31-20 08:52AM	Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment Zacks
Dec-28-20 07:30AM	Is Amgen Stock A Buy As The Biotech Company Deepens Its Cancer Focus? Investor's Business Daily
07:00AM	Is Gilead Stock A Buy As The Company Expands Through Buyouts? Investor's Business Daily
Dec-22-20 09:08AM	3 Large Drugmakers Set to Rule the Sector in 2021 Zacks
Dec-21-20 10:16AM	Novartis (NVS) Gets CRL From the FDA for Cholesterol Drug Zacks
Dec-18-20 07:04PM	FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now Motley Fool
05:08PM	U.S. FDA declines approval of Novartis' cholesterol-lowering drug Reuters
04:50PM	Novartis receives complete response letter from U.S. FDA for inclisiran GlobeNewswire
07:34AM	Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN Zacks
Dec-17-20 12:29PM	A new coalition takes on social justice in medicine Yahoo Finance
09:25AM	Novartis (NVS) to Acquire Neuroscience Company for Up to $770M Zacks
Dec-16-20 01:31PM	Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use Zacks
07:15AM	The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga
Dec-15-20 07:17PM	Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF GlobeNewswire
10:37AM	Novartis' (NVS) COVID-19 Study Fails to Meet Primary Endpoint Zacks
07:27AM	20 Biggest Healthcare Companies By Revenue Insider Monkey
01:15AM	Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema GlobeNewswire
Dec-14-20 01:15AM	Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 GlobeNewswire
Dec-11-20 09:29AM	Pharma Stock Roundup: FDA Panel's Nod to PFE/BNTX Coronavirus Vaccine, Other Updates Zacks
Dec-09-20 09:45AM	Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer GlobeNewswire
09:00AM	Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer GlobeNewswire
Dec-08-20 04:23PM	4 Central European Stocks Broadly Owned by Gurus GuruFocus.com
10:00AM	Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial GlobeNewswire
Dec-05-20 10:00AM	Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas GlobeNewswire
Dec-04-20 12:30PM	Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD GlobeNewswire
08:00AM	New Results on Blood Disorder Treatments Are Coming. Watch These Stocks. Barrons.com
Dec-03-20 04:33PM	Kinnate Biopharma Stock Doubles As IPO Begins Trading Investor's Business Daily
04:12AM	Glaxo downgraded to neutral at UBS, which says European pharma 'cheap but not a bargain' MarketWatch
Dec-02-20 04:09PM	Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion Zacks
Nov-25-20 09:30AM	Should Value Investors Consider Novartis (NVS) Stock Now? Zacks
Nov-24-20 08:12AM	The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga
07:13AM	Novartis Kicks Off $2.5B Share Buyback Program On Strong Pipeline Growth Benzinga
01:00AM	Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event GlobeNewswire
Nov-23-20 07:00PM	Mesoblast (MESO) Q1 2021 Earnings Call Transcript Motley Fool
Nov-20-20 11:20AM	Why Mesoblast Stock Is Blasting Off Today Motley Fool
10:17AM	Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy Zacks
09:44AM	Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More Zacks
08:42AM	20 Largest European Companies By Market Cap in 2020 Insider Monkey
07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga
Nov-19-20 04:30PM	Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy GlobeNewswire
10:00AM	Price Over Earnings Overview: Novartis Benzinga
09:43AM	New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases GlobeNewswire
01:15AM	Novartis set to achieve 100% renewable electricity in its European operations GlobeNewswire
Nov-18-20 01:29AM	15 Largest Biotech Companies in the World Insider Monkey
Nov-16-20 01:54PM	15 Largest Drug Companies in the World Insider Monkey
Nov-15-20 06:52AM	Is Novartis' Dividend at Risk? Motley Fool
Nov-13-20 10:00AM	New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender GlobeNewswire
Nov-10-20 05:06PM	Alcon: Q3 Earnings Insights Benzinga
04:46PM	How Biotech Giant Amgen Could Take On Regeneron In Asthma Treatment Investor's Business Daily
Nov-06-20 07:47AM	The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga
02:00AM	Novartis arthritis drug fails to help COVID-19 patients Reuters
01:15AM	Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) GlobeNewswire
Nov-05-20 04:11PM	Incyte Earnings Miss Expectations; Tightens Outlook For Top Product Investor's Business Daily
10:12AM	Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong Zacks
09:57AM	Ionis (IONS) Misses Estimates for Q3 Earnings and Sales Zacks
01:15AM	Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study GlobeNewswire
Nov-03-20 10:54AM	The Zacks Analyst Blog Highlights: PayPal, Comcast, Novartis, BlackRock and FedEx Zacks
Nov-02-20 04:33PM	Novartis Expands Presence in Gene Therapy With Acquisition GuruFocus.com
02:45PM	Top Analyst Reports for PayPal, Comcast & Novartis Zacks
01:27PM	The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J Zacks
01:15AM	Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention GlobeNewswire
Oct-30-20 01:06PM	Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study Zacks
11:23AM	Pharmaceutical Industry Leaders Target Cutting-Edge MS Treatments That Once Were 'Fantasy' Investor's Business Daily
02:15AM	Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia GlobeNewswire
Oct-29-20 10:51AM	Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results? Zacks
08:32AM	Novartis Snaps Up Vedero Bio In $280M Deal; Street Says Buy SmarterAnalyst
07:30AM	The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga
04:32AM	Novartis buys Vedere Bio, whose founders helped blind mice see Reuters
Oct-28-20 07:41AM	The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts Benzinga
04:53AM	Novartis Strikes Deal To Commercialize Molecular Partners' COVID-19 Drug Candidates Benzinga
02:35AM	Molecular Partners jumps after Novartis deal for potential COVID-19 drugs Reuters
02:15AM	Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 GlobeNewswire
Oct-27-20 04:29PM	Novartis Earnings Top, Sales Miss; NVS Stock Falls Investor's Business Daily
10:49AM	Novartis' (NVS) Q3 Earnings Surpass Estimates, Sales Miss Zacks
07:59AM	Novartis: Q3 Earnings Insights Benzinga
02:11AM	Novartis upbeat as drugmakers see hospitals coping with COVID Reuters
02:00AM	Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance. GlobeNewswire
Oct-26-20 02:15AM	Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G) GlobeNewswire
Oct-23-20 09:08AM	Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug Zacks
Oct-19-20 01:05PM	The Zacks Analyst Blog Highlights: Novartis, Zoom Video, FIS, 3M and TOTAL Zacks
Oct-16-20 01:31PM	Top Research Reports for Novartis, Zoom Video & FIS Zacks
Oct-15-20 09:00AM	Influencers with Andy Serwer: Richard Davis Yahoo Finance Video
Oct-12-20 05:47PM	Top 5 Sells of the Tweedy Browne Global Value Fund GuruFocus.com
Oct-06-20 06:44PM	Hedge Funds Have Never Been Less Bullish On Novartis AG (NVS) Insider Monkey
10:31AM	GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status Zacks
Oct-03-20 06:20AM	Will Big Pharma Acquire Novavax? Motley Fool
Oct-02-20 09:52AM	Congressional Committee Accuses Amgen and Peers of Hiking Drug Prices to Meet "Aggressive" Revenue Targets Motley Fool
Oct-01-20 01:15AM	Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement GlobeNewswire

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; Dyno Therapeutics Inc.; and Olema Oncology. The company was founded in 1895 and is headquartered in Basel, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novartis Bioventures Ltd	Former 10% Owner	Jun 30	Buy	17.00	125,000	2,125,000	1,181,258	Jul 02 04:16 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience